Endocrinology, Vol 133, 1158-1164, Copyright © 1993 by Endocrine Society

ARTICLES

The mechanism for the disparate actions of calcitriol and 22- oxacalcitriol in the intestine

AJ Brown, J Finch, M Grieff, C Ritter, N Kubodera, Y Nishii and E Slatopolsky
Renal Division, Washington University School of Medicine, St. Louis, Missouri 63110.

22-Oxacalcitriol (OCT) is one of several new analogs of vitamin D that retain many of the therapeutically useful properties of 1,25- dihydroxyvitamin D3 [1,25-(OH)2D3], but have much less calcemic activity. In the present study we examined the actions of OCT on intestinal calcium absorption and calbindin D9k mRNA in vitamin D- deficient rats. After ip injection of OCT (1 microgram/kg), calcium absorption increased significantly by 2 h and was maximal at 4 h (2.5- fold above control), but returned to pretreatment levels by 16 h. In contrast, the same dose of 1,25-(OH)2D3 caused a 3-fold increase in calcium absorption, which lasted more than 48 h. The transient effect of OCT on calcium absorption was also observed when the analog was infused at a dose of 1 micrograms/kg.day for 3 days. At the end of the infusion period, calcium absorption was 3-fold higher than that in vehicle-infused controls, but fell to pretreatment levels by 24 h after removing the minipumps. The time courses for induction of calbindin D9k mRNA were similar for OCT and 1,25-(OH)2D3, with no change observed until more than 4 h after injection. However, calbindin mRNA levels returned to pretreatment values more rapidly in the OCT-treated rats. Consistent with these findings, we observed that a 1 microgram/kg dose of [3H] OCT was completely cleared by 4-6 h after injection. This was paralleled by a loss of [3H]OCT associated with the intestinal vitamin D receptor. The rapid clearance of OCT is probably due to its low affinity for the serum vitamin D-binding protein. This low affinity would also be expected to allow greater accessibility to target cells. In support of this, we found that higher amounts of OCT than 1,25- (OH)2D3 were associated with the intestinal vitamin D receptor after the injection of several doses of these tritiated ligands. In summary, our results indicate that the pharmacokinetic properties of OCT are responsible at least in part for its low calcemic activity. Furthermore, comparison of the transient elevation of calcium absorption by OCT with its more prolonged effects on PTH and calbindin D9k indicates that each action of vitamin D compounds has a distinct biological half-life. The short circulating half-life of OCT can exploit these differences to provide a therapeutic advantage in the treatment of vitamin D-responsive diseases.

This article has been cited by other articles:

				Z. H. Al-oanzi, S. P. Tuck, N. Raj, J. S. Harrop, G. D. Summers, D. B. Cook, R. M. Francis, and H. K. Datta Assessment of Vitamin D Status in Male Osteoporosis Clin. Chem., February 1, 2006; 52(2): 248 - 254. [Abstract] [Full Text] [PDF]

				A. S. Dusso, A. J. Brown, and E. Slatopolsky Vitamin D Am J Physiol Renal Physiol, July 1, 2005; 289(1): F8 - F28. [Abstract] [Full Text] [PDF]

				S. Peleg, M. Uskokovic, A. Ahene, B. Vickery, and Z. Avnur Cellular and Molecular Events Associated with the Bone-Protecting Activity of the Noncalcemic Vitamin D Analog Ro-26-9228 in Osteopenic Rats Endocrinology, May 1, 2002; 143(5): 1625 - 1636. [Abstract] [Full Text] [PDF]

				S. J. Steddon, N. J. Schroeder, and J. Cunningham Vitamin D analogues: how do they differ and what is their clinical role? Nephrol. Dial. Transplant., October 1, 2001; 16(10): 1965 - 1967. [Full Text] [PDF]

				J. L. FINCH, A. S. DUSSO, T. PAVLOPOULOS, and E. A. SLATOPOLSKY Relative Potencies of 1,25-(OH)2D3 and 19-Nor-1,25-(OH)2D2 on Inducing Differentiation and Markers of Bone Formation in MG-63 Cells J. Am. Soc. Nephrol., July 1, 2001; 12(7): 1468 - 1474. [Abstract] [Full Text] [PDF]

				K. Makibayashi, M. Tatematsu, M. Hirata, N. Fukushima, K. Kusano, S. Ohashi, H. Abe, K. Kuze, A. Fukatsu, T. Kita, et al. A Vitamin D Analog Ameliorates Glomerular Injury on Rat Glomerulonephritis Am. J. Pathol., May 1, 2001; 158(5): 1733 - 1741. [Abstract] [Full Text] [PDF]

				A. J. BROWN, J. FINCH, F. TAKAHASHI, and E. SLATOPOLSKY Calcemic Activity of 19-Nor-1,25(OH)2D2 Decreases with Duration of Treatment J. Am. Soc. Nephrol., November 1, 2000; 11(11): 2088 - 2094. [Abstract] [Full Text]

				L. S. HOLLIDAY, S. L. GLUCK, E. SLATOPOLSKY, and A. J. BROWN 1,25-Dihydroxy-19-nor-vitamin D2, a Vitamin D Analog with Reduced Bone Resorbing Activity In Vitro J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1857 - 1864. [Abstract] [Full Text]

				N. J. Schroeder and J. Cunningham What's new in vitamin D for the nephrologist? Nephrol. Dial. Transplant., April 1, 2000; 15(4): 460 - 466. [Full Text] [PDF]

				A. J. Brown, A. Dusso, and E. Slatopolsky Vitamin D Am J Physiol Renal Physiol, August 1, 1999; 277(2): F157 - F175. [Abstract] [Full Text] [PDF]

				J. L. FINCH, A. J. BROWN, and E. SLATOPOLSKY Differential Effects of 1,25-Dihydroxy-Vitamin D3 and 19-Nor-1,25-Dihydroxy-Vitamin D2 on Calcium and Phosphorus Resorption in Bone J. Am. Soc. Nephrol., May 1, 1999; 10(5): 980 - 985. [Abstract] [Full Text]